Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Accumulated Expenses: 2019-2024

Historic Accumulated Expenses for Keros Therapeutics (KROS) over the last 6 years, with Dec 2024 value amounting to $20.9 million.

  • Keros Therapeutics' Accumulated Expenses fell 31.55% to $15.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.2 million, marking a year-over-year decrease of 31.55%. This contributed to the annual value of $20.9 million for FY2024, which is 16.48% up from last year.
  • As of FY2024, Keros Therapeutics' Accumulated Expenses stood at $20.9 million, which was up 16.48% from $17.9 million recorded in FY2023.
  • In the past 5 years, Keros Therapeutics' Accumulated Expenses ranged from a high of $20.9 million in FY2024 and a low of $4.6 million during FY2020.
  • Moreover, its 3-year median value for Accumulated Expenses was $17.9 million (2023), whereas its average is $17.2 million.
  • Data for Keros Therapeutics' Accumulated Expenses shows a peak YoY soared of 128.09% (in 2020) over the last 5 years.
  • Keros Therapeutics' Accumulated Expenses (Yearly) stood at $4.6 million in 2020, then skyrocketed by 59.13% to $7.3 million in 2021, then soared by 73.77% to $12.8 million in 2022, then surged by 40.50% to $17.9 million in 2023, then grew by 16.48% to $20.9 million in 2024.